Check your likely Japan PR eligibility
Use the calculator to estimate your points before you plan your next step.
Japan’s health ministry on April 15, 2026 published the minutes from its January 29, 2026 review meeting on safety controls for thalidomide-, lenalidomide- and pomalidomide-based medicines, showing the panel backed a framework for pending generic pomalidomide approvals and endorsed a tightly limited path for outside-hospital dispensing and home-care cases. The official meeting index and materials also show officials are preparing updates to the TERMS and RevMate safety systems after a 2024 pregnancy case involving a male Revlimid patient’s partner.
Key developments
- For generic pomalidomide, the committee agreed the default approach should mirror earlier lenalidomide generics: use RevMate-based controls as the baseline, while allowing Fujimoto Pharmaceutical’s product to use TERMS if its approval conditions match other generics. According to the minutes, the final TERMS and RevMate revision draft is expected to go through public comment and then to the Pharmaceutical Affairs and Food Sanitation Council’s safety panel.
- The panel also approved a special-case route for patients who can no longer complete treatment entirely inside a hospital. Under 資料2, outside pharmacies could serve as the “responsible pharmacist” in exceptional cases, and home-visit workflows could be handled patient by patient before full manual revisions and system changes are finished.
- That new route is not open-ended. Officials said each case would need review by the relevant joint operating committee and reporting to a third-party evaluation committee. The material also limits some home-visit use cases to patients in the A male or B female categories, not C female patients.
- In a separate report item, MHLW said it has already issued alerts and revised patient education materials after a May 2024 pregnancy case. Planned updates include explicit education at treatment discontinuation, new post-treatment compliance confirmation forms for A male and C female patients, and clearer rules that pregnancy tests for C female patients should in principle be conducted at the prescribing medical institution.
What to watch
The next step is not full implementation but further rulemaking. The ministry said revised TERMS and RevMate drafts still need public comment and additional review, while broader manual changes and system modifications for outside-hospital and home-care handling could take years.
Another issue is operational readiness. Committee members warned that many community pharmacies have little or no experience handling these medicines, and the minutes show officials expect outreach to pharmacists and coordination among companies, providers and authorities before exceptional cases can work smoothly in practice.
Sources
About this content
Japan PR Checker
Japan Permanent Residency Checker - Check your eligibility for Japan PR in minutes!
Want the practical next step?
If you are comparing routes, timelines, or likely eligibility, use the calculator now so your planning starts from a clearer baseline.